Inhibitory effects of adenovirus mediated Akt1 and PIK3R1 shRNA on the growth of malignant tumor cells in vitro and in vivo

Cancer Biology and Therapy

Volumn 8, Issue 11, 2009, Pages 1002-1009

  Fu, Yanchao ^a   Zhang, Qingyu ^a   Kang, Chunsheng ^a,b   Zhang, Jing ^a   Zhang, Kairu ^a   Pu, Peiyu ^a,b   Wang, Guangxiu ^a,b   Wang, Tao ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b Tianjin Neurological Institute   (China)

Author keywords

Gene therapy; Invasion; Malignant tumor; Proliferation; RNA interference

Indexed keywords

ADENOVIRUS VECTOR; CYCLIN D1; CYCLINE; GELATINASE A; GELATINASE B; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P53; SHORT HAIRPIN RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; STATISTICAL ANALYSIS; SURVIVAL RATE; TUMOR XENOGRAFT; VIRAL GENE THERAPY; WESTERN BLOTTING;

ADENOCARCINOMA; ADENOVIRIDAE; ANIMALS; BASE SEQUENCE; CELL LINE, TUMOR; GENE THERAPY; GLIOBLASTOMA; HUMANS; MICE; MICE, NUDE; MOLECULAR SEQUENCE DATA; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RNA INTERFERENCE; RNA, SMALL INTERFERING; STOMACH NEOPLASMS; TRANSFECTION;

EID: 68049135982     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.8.11.8285     Document Type: Article

References (32)

1. Khalighinejad N, Hariri H, Behnamfar O, Yousefi A, Momeni A. Amir Momeni Adenoviral gene therapy in gastric cancer. World J Gastroenterol 2008; 14:180-4.
2. Yonemura Y, Wu CC, Fukushima N, Honda I, Bandou E, Kawamura T. Randomized clinical trial of D2 and extended paraaortic lymphadenectomy in patients with gastric cancer. Int J Clin Oncol 2008 13:132-7.
3. Tajima Y, Yamazaki K, Makino R, Nishino N, Aoki S, Kato M. Gastric and intestinal phenotypic marker expression in early differentiated-type tumors of the stomach: clinicopathologic significance and genetic background. Clin Cancer Res 2006; 12:6469-79.
4. Bernstein E, Caudy AA, Hammond SM, Hannon GJ. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 2001; 409:363-6.
5. Hammond SM, Bernstein E, Beach D, Hannon GJ. An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature 2000; 404:293-6.
6. Bernstein E, Denli AM, Hannon GJ. The rest is silence. RNA 2001; 7:1509-21.
7. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391:806-11.
8. Zamore PD. RNA interference: listening to the sound of silence. Nat Struct Biol 2001; 8:746-51.
9. Sijen T, Fleenor J, Simmer F, Thijssen KL, Parrish S, Timmons L. On the role of RNA amplification in dsRNA-triggered gene silencing. Cell 2001; 107:465-76.
10. Cully M, You H, Levine AJ, Mak TW. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 2006; 6:184-92.
11. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2:489-501.
12. Fingar DC, Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 2004; 23:3151-71.
13. Duan C, Bauchat JR, Hsieh T. Phosphatidylinositol 3-kinase is required for insulin-like growth factor-I-induced vascular smooth muscle cell proliferation and migration. Circ Res 2000; 86:15-23.
14. Cartwright JE, Tse WK, Whitley GS. Hepatocyte growth factor induced human trophoblast motility involves phosphatidylinositol-3-kinase, mitogen-activated protein kinase, and inducible nitric oxide synthase. Exp Cell Res 2002; 279:219-26.
15. Qiu Q, Yang M, Tsang BK, Gruslin A. EGF-induced trophoblast secretion of MMP-9 and TIMP-1 involves activation of both PI3K and MAPK signalling pathways. Reproduction 2004; 128:355-63.
16. Dirk G, Mark AK. Therapeutic application of RNAi: is mRNA targeting finally ready for prime time? J Clin Invest 2007; 117:3633-41.
17. Almeida R, Allshire RC. RNA silencing and genome regulation. Trends Cell Biol 2005; 15:251-8.
18. Zhang H, Kolb FA, Jaskiewicz L, Westhof E, Filipowicz W. Single processing center models for human Dicer and bacterial RNase III. Cell 2004; 118:57-68.
19. Lars A, John J. Rossi. RNAi Therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev 2007; 59:75-86.
20. Tang G. siRNA and miRNA: an insight into RISCs. Trends Biochem Sci 2005; 30:106-14.
21. Schwarz DS, Hutvágner G, Du T, Xu Z, Aronin N, Zamore PD. Asymmetry in the assembly of the RNAi enzyme complex. Cell 2003; 115:199-208.
22. Khvorova A, Reynolds A, Jayasena SD. Functional siRNAs and miRNAs exhibit strand bias. Cell 2003; 115:209-16.
23. Richard CM. The basic science of gene therapy. Science 1993; 260:926-32.
24. Yang YC, Huang WF, Chuan LM, Xiao DW, Zeng YL, Zhou DA. In vitro and in vivo study of cell growth inhibition of simvastatin on chronic myelogenous leukemia cells. Chemotherapy 2008; 54:438-46.
25. Oliveira MG, Lauxen Ida S, Chaves AC, Rados PV, Sant'Ana Filho M. Immunohistochemical analysis of the patterns of p53 and PCNA expression in odontogenic cystic lesions. Med Oral Pathol Oral Cir Bucal 2008; 13:275-80.
26. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 1994; 266:1821-37.
27. Lebeau A, Unholzer A, Amann G, Kronawitter M, Bauerfeind I, Sendelhofert A. EGFR, HER-2/neu, Cyclin D1, p2l and p53 in correlation to cell proliferation and steroid hormone receptor status in ducta1 carcinoma in situ of the breast. Breast Cancer Res Treat 2003; 79:187-98.
28. Yamamoto H, Ochiya T, Takeshita F, Toriyama-Baba H, Hirai K, Sasaki H. Enhanced skin carcinogenesis in Cyclin D1-conditional transgenic mice: Cyclin Dl alters keratinocyte response to calcium-induced terminal differentiation. Cancer Res 2002; 62:1641-7.
29. Mott JD, Werb Z. Regulation of matrix biology by matrix metalloproteinases. Curr Opin Cell Biol 2004; 16:558-64.
30. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006; 69:562-73.
31. Cawston TE, Wilson AJ. Understanding the role of tissue degrading enzymes and their inhibitors in development and disease. Best Pract Res Clin Rheumatol 2006; 20:983-1002.
32. Baker EA, Stephenson TJ, Reed MW, Brown NJ. Expression of proteinases and inhibitors in human breast cancer progression and survival. Mol Pathol 2002; 55:300-4.